Unione Europea - maltese - EMA (European Medicines Agency)

therakind (europe) limited - methotrexate - arthritis, psoriatic; precursor cell lymphoblastic leukemia-lymphoma; psoriasis; arthritis, rheumatoid; arthritis - aġenti antineoplastiċi - fl-rheumatological u dermatoloġiċi diseasesactive ' l-artrite rewmatika f'pazjenti adulti. polyarthritic forom severi, attivi-artrite idjopatika ġuvenili (jia) fl-adoloxxenti u tfal b'età minn 3 snin u l-fuq minn meta r-rispons għal mediċini mhux sterojdi kontra l-infjammazzjoni (nsaids), kienet inadegwata. severi, it-trattament refrattarji, diżabilità tal-psorijasi u li ma jirrispondix biżżejjed għall-forom oħra ta ' kura bħal fototerapija, psoralen u mir-radjazzjoni ultravjola (puva) it-terapija u l-retinojdi, u severa l-artrite psorjatika f'pazjenti adulti. fl-oncologymaintenance-trattament ta ' lewkimja akuta limfoblastika (all) fl-adulti, l-adoloxxenti u t-tfal b'età minn 3 snin u aktar.

Unione Europea - maltese - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigens tal-wiċċ tal-virus tal-influwenza (emagglutinin u neuraminidase) ta 'razza a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini - immunizzazzjoni attiva kontra s-sottotip h5n1 tal-virus influwenza a.. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Unione Europea - maltese - EMA (European Medicines Agency)

steba biotech s.a - padeliporfin di-potassium - neoplasmi prostatiċi - aġenti antineoplastiċi - tookad huwa indikat bħala monoterapija għall-pazjenti adulti li ma ġietx ikkurata qabel, unilaterali, riskju baxx, l-adenokarċinoma tal-prostata bil-għomor tal-ħajja ≥ 10 snin u:kliniċi stadju t1c jew t2a;gleason score ≤ 6, ibbażata fuq l-għolja tal-riżoluzzjoni tal-bijopsija l-istrateġiji;psa ≤ 10 ng/ml;3 pożittivi kanċer tal-cores b'massimu tal-kanċer tal-qalba it-tul ta '5 mm fil-ebda wieħed mill-qalba jew 1-2 pożittivi kanċer tal-cores ta' ≥ 50 % tal-kanċer l-involviment fl-ebda wieħed mill-qalba jew psa densità ≥ 0. 15 ng/ml/m3.

Unione Europea - maltese - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - aġenti antineoplastiċi - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Unione Europea - maltese - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaċċini - active immunisation against h5 subtype of influenza a virus.